Apellis Pharmaceuticals - Company & Market Research Reports

Apellis Pharmaceutical was founded in 2009 in Crestwood, U.S.A. It is a company with the aim of innovating and creating products to treat autoimmune and inflammatory diseases. Our lead compounds are designed to broadly inhibit complement C3, which is the central protein in the complement system.The complement system plays a key role in a wide range of autoimmune and inflammatory diseases. They believe with the use of C3 inhibition it may correct the immunological dysfunction. The approach they apply to this process is known as complement immunotherapy.


Kidney Transplant Rejection - Pipeline Review, H2 2017 - Product Thumbnail Image

Kidney Transplant Rejection - Pipeline Review, H2 2017

  • Report
  • 171 Pages
From
Transplantation Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Transplantation Drug Development Pipeline Review, 2017

  • Report
  • 242 Pages
From
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2018 - Product Thumbnail Image

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2018

  • Report
  • 94 Pages
From
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018 - Product Thumbnail Image

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Ophthalmology Drug Development Pipeline Review, 2016 - Product Thumbnail Image

Ophthalmology Drug Development Pipeline Review, 2016

  • Report
  • 633 Pages
From
IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments - Product Thumbnail Image

IgA Nephropathy Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

  • Report
  • 97 Pages
From
Renal Cluster Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Renal Cluster Drug Development Pipeline Review, 2017

  • Report
  • 181 Pages
From
Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2017

  • Report
  • 466 Pages
From
Pulmonary Fibrosis - Pipeline Review, H2 2016 - Product Thumbnail Image

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • Report
  • 377 Pages
From
Myasthenia Gravis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - Product Thumbnail Image

Myasthenia Gravis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • Report
  • 90 Pages
From
Systemic Lupus Erythematosus - Pipeline Review, H1 2018 - Product Thumbnail Image

Systemic Lupus Erythematosus - Pipeline Review, H1 2018

  • Report
  • 446 Pages
From
Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030 - Product Thumbnail Image

Back of the Eye Disorders: Novel Drugs and Delivery Technologies, 2017-2030

  • Report
  • 292 Pages
From
Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview  - Product Thumbnail Image

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

  • Report
  • 208 Pages
From
Age Related Macular Degeneration - Pipeline Review, H2 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H2 2017

  • Report
  • 537 Pages
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
Age Related Macular Degeneration - Pipeline Review, H1 2017 - Product Thumbnail Image

Age Related Macular Degeneration - Pipeline Review, H1 2017

  • Report
  • 527 Pages
From
Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2016

  • Report
  • 136 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2016

  • Report
  • 267 Pages
From
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016 - Product Thumbnail Image

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2016

  • Report
  • 141 Pages
From
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016 - Product Thumbnail Image

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016

  • Report
  • 254 Pages
From
Loading Indicator
adroll